DataMeds Wins Consent for Axe Compute Note Conversion With Full-Ratchet Reset
MEDS sits 27% above its 52-week low of $0.553.
Summary
Majority stockholders approved converting the $1.36M Axe Compute note into stock, and the note's full-ratchet reset means any future discounted issuance pushes more shares to Axe Compute.
Key Events · Financing and Capital Events · MEDS
-
Consent Clears Axe Compute Conversion
Holders of a majority of the common stock approved by written consent dated October 19, 2026 the issuance of shares upon conversion of the $1,363,672 Axe Compute note, satisfying Nasdaq Listing Rule 5635(a).
-
Conversion Price Sits Above Market
The initial conversion price is $1.00 per share against a $0.7001 current price, so the principal alone converts into 1,363,672 shares; accrued interest at 7% adds more unless the company pays it in cash.
-
Full-Ratchet Reset Compounds Dilution
The note's conversion price automatically drops to any lower effective price at which the company later issues stock, rather than adjusting on a weighted-average basis, so future discounted raises increase the share count owed to Axe Compute.
-
Axe Compute Stake Reaches 28.21%
Axe Compute holds 636,328 shares from the Helomics deal plus 1,363,672 conversion shares, or 28.21% of 7,088,529 shares on an as-converted basis, with more possible for interest and price resets.
Analysis · MEDS · Trade & Services
Holders of a majority of the common stock consented on October 19, 2026 to the share issuance behind the $1,363,672 Axe Compute note, clearing the Nasdaq 20% threshold. Once the approval takes effect, roughly 20 days after the information statement is mailed, the note converts automatically. The terms are the problem: the $1.00 conversion price sits well above the $0.7001 current price, and the note carries a full-ratchet reset that drops the conversion price to any lower price at which the company later sells stock. Any future discounted raise therefore hands Axe Compute more shares at that lower price, so dilution compounds with each financing. Axe Compute already holds 28.21% on an as-converted basis, and the company previously disclosed going-concern doubt with operations losing $3.4M in the quarter.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.70 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.55 to $35.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.